Delivery Order SPE2DB22D2206-SPE2DB25FJF02
Award Date 8/1/25
Potential Completion Date 8/22/25
Potential Value $3.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,464.38 for Xolair 300 mg/2 mL syringes on August 1, 2025, with an ultimate completion date of August 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used primarily for treating moderate-to-severe allergic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,440.70 for Xolair 150 mg/ml syringes on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used primarily for treating...
- The Defense Logistics Agency awarded a delivery order valued at $10,393.14 to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL syringes on July 22, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 12, 2025, with performance occurring at the vendor's location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used in the treatment of moderate-to-severe asthma and other allergic conditions, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes on August 18, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xolair (omalizumab) is a biologic medication used primarily in the treatment of allergic asthma and chronic...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and other allergic...
- The Defense Logistics Agency awarded a $11,159.12 delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL autoinjectors on August 5, 2025, with completion targeted for August 26, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe asthma and chronic urticaria,...
- The Defense Logistics Agency awarded a delivery order valued at $1,440.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes on August 4, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe allergic asthma and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,203.40 for XOLAIR 150 mg/ml syringes under a firm fixed price contract on August 8, 2025, with an ultimate completion date of August 29, 2025. This is a competitive award with no set-aside designation, and performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic...
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes valued at $1,800.88, with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used in the treatment of moderate to severe allergic asthma...